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levels of susceptibility because the
MIC50 was only 1 dilution below the
current breakpoint (7,8). Aztreonam
resistance could not be transferred by
conjugation between IMP-1–produc-
ing (aztreonam-resistant) P.  putida
and P. aeruginosa (2) and is not asso-
ciated with a transposon carrying
blaVIM-2 (6). No evidence of extend-
ed-spectrum β-lactamases was detect-
ed in our isolates by classic synergy
assays with clavulanate plus aztreon-
am, ceftazidime, or cefotaxime. VIM-
6–producing  P.  putida isolates from
Singapore (9) were more resistant to
aztreonam (MIC >128 µg/mL), cef-
tazidime, and cefepime (MIC >256
µg/mL).
Detection of blaVIM-2 in
Pseudomonas in South America was
initially reported by the SENTRY
Antimicrobial Surveillance Program
(10) and included 1 P. fluorescens iso-
late in Chile and 3 P. aeruginosa iso-
lates in Venezuela. To the best of our
knowledge, our report is the first of
VIM-2 in P. putida in Latin America.
VIM-2–producing  P.  putida, which
were originally restricted to East Asia
and only very recently found in
France, may represent an emerging
pathogen or function as reservoirs for
resistance because of their widespread
presence in the hospital environment.
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Multidrug-resistant
Acinetobacter 
baumannii, Russia
To the Editor: During the past
decade, nosocomial infections due to
multidrug-resistant  Acinetobacter
baumannii have been described with
increasing frequency, mostly in inten-
sive care units (ICUs), resulting in
therapeutic difficulties (1). The main
mechanism for resistance to extend-
ed-spectrum cephalosporins in A.
baumannii is attributed to the overex-
pression of chromosome-encoded
cephalosporinases or to plasmid-
encoded Ambler class A, B, and D β-
lactamases (2). A. baumannii that pro-
duce PER-1 extended-spectrum β-lac-
tamase (ESBL) are rarely isolated
outside Turkey and remain suscepti-
ble to carbapenems (3). Here we
describe what we believe is the first
ESBL-producing  A. baumannii iso-
late resistant to carbapenems and the
first characterization of a PER-1 A.
baumannii isolate from Russia, fur-
ther supporting the emergence and
dissemination of PER-1 A. baumannii
strains in eastern Europe and outside
Turkey (3,4).
On April 17, 2005, a 79-year-old-
man was hospitalized in the cardiolo-
gy ward of a private hospital in
Moscow, Russia, with cardiac
arrhythmia and a pulmonary infarc-
tion subsequent to a pulmonary
embolism. After 1 week, he was trans-
ferred to the ICU for multiple organ
failure related to a nosocomial infec-
tion caused by an A. baumannii strainLETTERS
susceptible to several antimicrobial
drugs, including imipenem (with pos-
itive lung aspiration and blood cul-
tures). He received imipenem and
amikacin at high doses. On May 5,
2005, he was transferred to the inter-
nal medicine ward of the American
Hospital of Paris, Neuilly-sur-Seine,
France. On the day of admission, bac-
terial cultures taken from sputum
showed a multidrug-resistant A. bau-
mannii MOS-1 strain, susceptible
only to colistin and rifampin. The
patient received intravenous and
aerosolized colistin 3 times a day plus
rifampin at 1,200 mg/d so that he
could return to Russia. Rapid identifi-
cation of A. baumannii MOS-1,
increased awareness as a result of a
French national alert signaling the
emergence of ESBL VEB-1–produc-
ing A. baumannii (5), and implemen-
tation of strict barrier precautions pre-
vented dissemination of this strain.
No other multidrug-resistant A. bau-
mannii isolate with a similar resist-
ance profile has been isolated in the
hospital before, during, or after this
period.
A. baumannii MOS-1 was sus-
ceptible to colistin and rifampin only,
and no synergy image could be
observed between clavulanic acid and
cefepime or ceftazidime discs on a
routine antibiogram performed by the
disc diffusion method. Only the use of
cloxacillin-containing Mueller-
Hinton agar plates (200 µg/mL) to
inhibit the activity of the naturally
occurring cephalosporinase (AmpC)
allowed detection of a synergy image,
signature of the presence of an ESBL
(5). MICs for imipenem, determined
by the agar dilution method (6), were
>64 µg/mL. Clavulanic acid addition
(2 µg/mL) decreased ticarcillin MIC
from >512 to 256 µg/mL and cef-
tazidime MIC from 512 to 128 µg/mL
but did not affect MIC of imipenem.
Genes coding for ESBLs and for
class B and D carbapenemases were
sought by PCR as previously
described (4,5). Primers used for
detection of TEM and PER β-lacta-
mases gave 894-bp and 825-bp PCR
products, respectively (4). Sequence
analysis showed identity with blaTEM-1
and blaPER-1 genes (4). Results of iso-
electric focusing showed 3 isoelectric
point values (5.3 for PER-1, 5.4 for
TEM-1, and >8.5 for AmpC) in A.
baumannii MOS-1 (4). A crude β-lac-
tamase extract of that isolate had no
significant imipenem hydrolysis
activity, which suggests that the car-
bapenem resistance may have
emerged through a nonenzymatic
mechanism such as mutations in
porins (7).  BlaPER-1 gene in A. bau-
mannii MOS-1 was located on a com-
posite transposon, Tn1213, identical
to that characterized by Poirel et al.
(8). Attempts to demonstrate plasmids
or transfer genes encoding TEM-1 or
PER-1 failed (data not shown), which
suggests that the genes were chromo-
somally encoded. A. baumannii MOS-
1 was not clonally related to well-
characterized PER-1 A. baumannii
strains from Turkey, France, and Bel-
gium (4,9) (Figure), further supporting
genetic heterogeneity of PER-1 A.
baumannii  isolates, even though the
immediate genetic environment of
blaPER-1 gene was similar (8).
The emergence and spread of
ESBL-producing  A. baumannii
strains are of concern because they
will increase carbapenem use, thus
raising the risk for emergence of car-
bapenem-resistant isolates. A. bau-
mannii MOS-1 is, we believe, the first
description of an ESBL-producing A.
670 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 13, No. 4, April 2007
Figure. Pulsed-field gel electrophoresis of ApaI restricted analysis of Acinetobacter bau-
mannii isolates. Lane 1, A. baumannii AMA-1 from France (4); lanes 2 and 3, A. bauman-
nii  IST-1 and A. baumannii IST-2 from Turkey (4); lane 4, A. baumannii isolate from
Belgium (4); lane 5, A. baumannii MOS-1 from Russia (current study); lane M, bacterio-
phage lambda molecular mass ladder. Numbers on the right side of the figure represent
the sizes in kb. LETTERS
baumannii isolate also being resistant
to carbapenems. This resistance was
likely acquired in vivo under imipen-
em treatment, but the susceptible
strain was not available for strain
comparison. This is also the first
description of a PER-1 A. baumannii
isolate from Russia, a country from
which little epidemiologic data on
antimicrobial drug resistance are
available, except for the emergence of
ESBLs of CTX-M type in
Enterobacteriaceae (10).
This study highlights the impor-
tance of international patient transfer
in the spread of antimicrobial drug
resistance, thus emphasizing the need
for hospitals to isolate and screen for
multidrug-resistant pathogens in all
patients admitted to hospitals from
foreign countries. This is particularly
critical when the foreign country is
known for a high prevalence of mul-
tidrug-resistant bacteria or when no
antimicrobial drug resistance data are
available.
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Human Infection
with Rickettsia sp.
related to R.
japonica, Thailand
To the Editor: Although rick-
ettsioses caused by scrub typhus and
typhus group rickettsiae are well rec-
ognized in Thailand, few spotted-
fever group rickettsiae (SFGR),
including Rickettsia honei TT118 and
R. felis, have been documented to be
associated with human illnesses (1,2).
We report a case of human infection
with an SFGR species closely related
to R. japonica in Thailand.
In January 2005, a 36-year-old
man with prolonged fever, pneumo-
nia, and septic shock was transferred
from a private hospital to
Phramongkutklao Army Hospital in
Bangkok. Two weeks before the onset
of fever, the patient had camped at
Khao Yai National Park, ≈175 km
northeast of Bangkok. The park is a
popular location for tourists and the
largest national park declared as a nat-
ural wildlife reserve area. The patient
reported the presence of wild deer
around the camping area but did not
recall being bitten by an arthropod.
Ten days before hospitalization, he
developed flulike symptoms, fever,
and sore throat. Six days later, he
noted petechiae on his lower extremi-
ties, and his condition worsened. At
the time of hospital admission, the
patient had fever of 38.6°C, tachycar-
dia, dyspnea, hypotension, nausea,
vomiting, generalized maculopapular
rash, and subconjunctival hemor-
rhage. Laboratory investigation
showed thrombocytopenia (platelets
64,000/mm3), leukocytosis (14,000/
mm3), and elevated levels of serum
hepatic enzymes (aspartate amino-
transferase 287 IU/L [reference 5–50
IU/L]; alanine aminotransferase 186
IU/L [reference 5–40 IU/L]). Chest
radiograph showed interstitial pneu-
monitis. Serum antibody test results
were negative for leptospira and
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